Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Levodopa/carbidopa extended-release - Amneal Pharmaceuticals

Next Previous
X
Search
Drug Profile

Levodopa/carbidopa extended-release - Amneal Pharmaceuticals

Alternative Names: Carbidopa/levodopa extended-release capsules - Amneal Pharmaceuticals; GSK-587124; IPX-066; NUMIENT; Patrome; Rytary

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Impax Pharmaceuticals
  • Developer Amneal Pharmaceuticals
  • Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 28 Jan 2019 Levodopa/carbidopa extended-release is not yet available for Parkinson's disease in Iceland, Norway, Liechtenstein and other European Union countries
  • 12 Jul 2018 Chemical structure information added
  • 21 Jun 2018 Amneal Pharmaceuticals enters into patent litigation settlement agreement with Actavis related to Actavis's submission of an ANDA to the US FDA seeking approval to market a generic version of Rytary® in the US

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top